Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $36.70.
Several equities analysts have recently weighed in on the stock. StockNews.com upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. TD Cowen began coverage on Alkermes in a research note on Monday, June 17th. They issued a “buy” rating and a $34.00 price objective for the company. HC Wainwright upped their target price on Alkermes from $35.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. lifted their price target on shares of Alkermes from $31.00 to $32.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price target on shares of Alkermes in a research note on Monday, September 16th.
Read Our Latest Research Report on ALKS
Institutional Investors Weigh In On Alkermes
Alkermes Stock Performance
ALKS stock opened at $27.53 on Friday. Alkermes has a 1-year low of $22.01 and a 1-year high of $32.88. The company has a current ratio of 2.99, a quick ratio of 2.61 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average price of $27.39 and a 200-day moving average price of $25.76. The firm has a market cap of $4.66 billion, a PE ratio of 10.88, a price-to-earnings-growth ratio of 0.59 and a beta of 0.46.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. The firm had revenue of $399.13 million for the quarter, compared to analyst estimates of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The company’s revenue was down 35.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.38 earnings per share. As a group, equities research analysts expect that Alkermes will post 2.36 earnings per share for the current year.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Read More
- Five stocks we like better than Alkermes
- The How and Why of Investing in Gold Stocks
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to Capture the Benefits of Dividend Increases
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.